Roble Belko & Company Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Short-Term Inflation-Protected Securities Index Fund
VTIP
|
+$1.4M |
| 2 |
JPMorgan Ultra-Short Income ETF
JPST
|
+$713K |
| 3 |
Vanguard International Dividend Appreciation ETF
VIGI
|
+$605K |
| 4 |
Vanguard Morningstar Mid-Cap Growth ETF
VOT
|
+$278K |
| 5 |
BlackRock Enhanced Equity Dividend Trust
BDJ
|
+$266K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Global X MLP & Energy Infrastructure ETF
MLPX
|
+$2.31M |
| 2 |
Vanguard Morningstar Large-Cap ETF
VV
|
+$1.94M |
| 3 |
Vanguard FTSE All-World ex-US ETF
VEU
|
+$1.66M |
| 4 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$1.51M |
| 5 |
Pfizer
PFE
|
+$1.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 2.17% |
| 2 | Technology | 1.61% |
| 3 | Industrials | 0.78% |
| 4 | Healthcare | 0.45% |
| 5 | Financials | 0.38% |
Similar funds
Roble Belko & Company's Q3 2020 Portfolio in Review
As of Q3 2020, Roble Belko & Company held 359 positions worth $341M, up 2.2% from $334M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Roble Belko & Company withdrew a net $14M in Q3 2020, closing 30 positions and reducing 64 holdings. Its most notable exit was State Street SPDR S&P Biotech ETF, an estimated $303K position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 2.2% of assets, up from 2% a quarter earlier, followed by Technology and Industrials.
Against the trend, Roble Belko & Company opened a new position in Vanguard Morningstar Mid-Cap Growth ETF worth $284K.
- Roble Belko & Company's largest Q3 2020 buy was Vanguard Morningstar Mid-Cap Growth ETF: 1,578 shares worth $284K.
- Roble Belko & Company added most to Vanguard Short-Term Inflation-Protected Securities Index Fund in Q3 2020, an estimated $1.4M increase.
- Roble Belko & Company's biggest Q3 2020 reduction was Global X MLP & Energy Infrastructure ETF, cutting an estimated $2.31M.
- Roble Belko & Company fully exited State Street SPDR S&P Biotech ETF in Q3 2020, selling an estimated $303K.
- Roble Belko & Company's ten largest holdings make up 57% of its $341M portfolio in Q3 2020.
- Roble Belko & Company opened 34 new positions and closed 30 in Q3 2020.
- Roble Belko & Company's portfolio value rose 2.2% quarter-over-quarter to $341M.
Based on Roble Belko & Company's 13F filing for Q3 2020, filed 10 Nov 2020.